$PFE Pfizer announced that the Ph 3 PALLAS trial of Ibrance + standard adjuvant endocrine therapy in HR+/HER2- early #BreastCancer is unlikely to show a stat sig improvement in the primary endpoint. #Fail

Market cap dropped $13B after hours on the news.

https://t.co/1jMDGBnX6N